Quoin Pharmaceuticals, Ltd. (QNRX) 10-Year Financial Performance & Capital Metrics

QNRX • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutQuoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.Show more

Revenue $0
EBITDA -$9M -1.7%
Net Income -$9M -3.2%
EPS (Diluted) -66.85 +80.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -120.55% +9.3%
ROIC -161.61% +10.3%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 84 (top 16%)
✓Trading at only 0.2x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-58.23%

EPS CAGR

10Y-

5Y-

3Y-

TTM-59.02%

ROCE

10Y Avg12.8%

5Y Avg-108.87%

3Y Avg-102.89%

Latest-94.73%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	-280K	0	-280K	0	0	0	0	0	0
Revenue Growth %	-	-	1%	-	1%	-	-	-	-	-
Cost of Goods Sold+	18.27K	89.13K	104.22K	125.72K	227.06K	0	0	0	0	0
COGS % of Revenue	-	-0.32%	-	-0.45%	-	-	-	-	-	-
Gross Profit+	-18.27K	-369.13K	-104.22K	-405.72K	-227.06K	0	0	0	0	0
Gross Margin %	-	1.32%	-	1.45%	-	-	-	-	-	-
Gross Profit Growth %	-	-19.2%	0.72%	-2.89%	0.44%	1%	-	-	-	-
Operating Expenses+	2.58M	16.22M	10.1M	16.22M	1.56M	1.67M	6.06M	9.26M	9.38M	9.53M
OpEx % of Revenue	-	-57.94%	-	-57.94%	-	-	-	-	-	-
Selling, General & Admin	1.06M	7.97M	4.2M	7.97M	1.51M	1.43M	4.5M	6.58M	6.07M	5.93M
SG&A % of Revenue	-	-28.46%	-	-28.46%	-	-	-	-	-	-
Research & Development	1.52M	8.26M	5.89M	8.26M	45.65K	244.16K	1.56M	2.67M	3.31M	3.6M
R&D % of Revenue	-	-29.49%	-	-29.49%	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-2.6M	15.32M	10.17M	15.32M	-1.56M	-1.67M	-6.06M	-9.26M	-9.38M	-9.53M
Operating Margin %	-	-54.7%	-	-54.7%	-	-	-	-	-	-
Operating Income Growth %	-	6.89%	-0.34%	0.51%	-1.1%	-0.07%	-2.63%	-0.53%	-0.01%	-0.02%
EBITDA+	-2.58M	15.41M	10.28M	15.44M	-1.33M	-1.57M	-5.96M	-9.15M	-9.27M	-9.43M
EBITDA Margin %	-	-55.02%	-	-55.15%	-	-	-	-	-	-
EBITDA Growth %	-	6.97%	-0.33%	0.5%	-1.09%	-0.17%	-2.81%	-0.54%	-0.01%	-0.02%
D&A (Non-Cash Add-back)	18.27K	89.13K	104.22K	125.72K	227.06K	104.04K	104.04K	104.04K	103.71K	100K
EBIT	-2.62M	-3.99M	-7.91M	-5.59M	-4.31M	-1.67M	-20.37M	-8.67M	-9.38M	-9.53M
Net Interest Income+	0	0	0	0	-412.29K	-1.19M	-1.09M	-618.34K	694.61K	558.49K
Interest Income	1.03K	0	0	0	0	0	0	95.75K	694.61K	558.49K
Interest Expense	0	0	0	0	412.29K	1.19M	1.09M	714.08K	0	0
Other Income/Expense	-19.3K	237.07K	-1.06M	2.54M	0	-425.35K	-15.4M	-123.79K	691.93K	565.99K
Pretax Income+	-2.62M	15.32M	10.17M	15.32M	-1.56M	-2.1M	-21.46M	-9.38M	-8.69M	-8.96M
Pretax Margin %	-	-54.7%	-	-54.7%	-	-	-	-	-	-
Income Tax+	0	147.94K	-1.17M	-161.14K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-2.62M	15.32M	10.17M	15.32M	-1.56M	-2.1M	-21.46M	-9.38M	-8.69M	-8.96M
Net Margin %	-	-54.7%	-	-54.7%	-	-	-	-	-	-
Net Income Growth %	-	6.85%	-0.34%	0.51%	-1.1%	-0.34%	-9.24%	0.56%	0.07%	-0.03%
Net Income (Continuing)	-2.62M	-4M	-7.91M	-5.59M	-1.56M	-2.1M	-21.46M	-9.38M	-8.69M	-8.96M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2108.97	10084.00	5450.81	7100.73	-440.29	-88.10	-28543.20	-22.97	-337.47	-66.85
EPS Growth %	-	5.78%	-0.46%	0.3%	-1.06%	0.8%	-322.99%	1%	-13.69%	0.8%
EPS (Basic)	-2108.97	10084.00	5450.81	7100.73	-440.29	-88.10	-28543.20	-22.97	-337.47	-66.85
Diluted Shares Outstanding	1.24K	1.52K	1.87K	2.16K	3.54K	20.02K	1.6K	403.88K	25.74K	133.96K
Basic Shares Outstanding	1.24K	1.52K	1.87K	2.16K	3.54K	20.02K	1.6K	403.88K	25.74K	133.96K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	3.12M	8.42M	8.22M	4.98M	5.38M	465.17K	8.2M	13.37M	11.29M	14.93M
Cash & Short-Term Investments	3.02M	8.04M	7.99M	4.77M	5.24M	323.83K	7.48M	12.85M	10.69M	14.06M
Cash Only	1.01M	1.63M	3.96M	4.77M	5.24M	323.83K	7.48M	2.86M	2.4M	3.62M
Short-Term Investments	2.01M	6.41M	4.03M	0	0	0	0	9.99M	8.29M	10.43M
Accounts Receivable	48.06K	172.01K	70.57K	57.8K	77.3K	0	0	0	0	0
Days Sales Outstanding	-	-224.22	-	-75.35	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	141.34K	0	0	32.58K	0
Total Non-Current Assets+	310.2K	393.12K	524.83K	538.7K	794.73K	912.65K	1.16M	1.09M	883.33K	783.33K
Property, Plant & Equipment	305.06K	356.75K	387.14K	413.19K	672.55K	1.94M	0	0	0	0
Fixed Asset Turnover	-	-0.78x	-	-0.68x	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	1.02M	912.65K	808.6K	704.56K	583.33K	483.33K
Long-Term Investments	5.14K	36.38K	137.69K	125.51K	122.18K	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	-1.02K	-1.94M	350K	383.39K	300K	300K
Total Assets+	3.43M	8.81M	8.75M	5.52M	6.17M	1.38M	9.36M	14.46M	12.17M	15.71M
Asset Turnover	-	-0.03x	-	-0.05x	-	-	-	-	-	-
Asset Growth %	-	1.57%	-0.01%	-0.37%	0.12%	-0.78%	5.79%	0.55%	-0.16%	0.29%
Total Current Liabilities+	735.02K	905.51K	1.18M	1.31M	1.05M	7.99M	4.58M	3.53M	3.58M	4.18M
Accounts Payable	119.76K	348.95K	490.55K	237.37K	45.74K	0	923.24K	605.6K	526.52K	905.7K
Days Payables Outstanding	2.39K	1.43K	1.72K	689.16	73.54	-	-	-	-	-
Short-Term Debt	0	15.07K	0	0	114.65K	1.21M	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	444.87K	541.49K	127.32K	1.07M	637.81K	0	373.6K	0	0	0
Current Ratio	4.25x	9.30x	6.97x	3.80x	5.11x	0.06x	1.79x	3.79x	3.15x	3.57x
Quick Ratio	4.25x	9.30x	6.97x	3.80x	5.11x	0.06x	1.79x	3.79x	3.15x	3.57x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	503.55K	2.14M	485.98K	824.84K	0	4.12M	3.52M	2.92M	2.32M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	196K	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	503.55K	2.14M	485.98K	628.84K	0	4.12M	3.52M	2.92M	2.32M
Total Liabilities	735.02K	1.41M	3.32M	1.8M	1.88M	7.99M	8.7M	7.05M	6.51M	6.5M
Total Debt+	0	15.07K	0	0	310.65K	1.21M	0	0	0	0
Net Debt	-1.01M	-1.62M	-3.96M	-4.77M	-4.93M	889.48K	-7.48M	-2.86M	-2.4M	-3.62M
Debt / Equity	-	0.00x	-	-	0.07x	-	-	-	-	-
Debt / EBITDA	-	0.00x	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-0.10x	-0.38x	-0.31x	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-3.78x	-1.41x	-5.56x	-12.96x	-	-
Total Equity+	2.7M	7.4M	5.43M	3.73M	4.3M	-6.61M	657.03K	7.41M	5.66M	9.2M
Equity Growth %	-	1.74%	-0.27%	-0.31%	0.15%	-2.54%	1.1%	10.27%	-0.24%	0.63%
Book Value per Share	2174.66	4876.01	2910.14	1727.38	1212.08	-329.97	411.42	18.34	220.04	68.71
Total Shareholders' Equity	2.7M	7.4M	5.43M	3.73M	4.3M	-6.61M	657.03K	7.41M	5.66M	9.2M
Common Stock	0	0	0	0	100	0	0	0	0	0
Retained Earnings	-5.24M	-9.28M	-18.42M	-22.49M	-29.2M	-6.61M	-28.07M	-37.52M	-46.2M	-55.17M
Treasury Stock	-2.42M	-2.45M	-2.71M	-2.52M	-2.73M	0	-2.93M	-2.93M	0	0
Accumulated OCI	972.49K	1.62M	2.7M	3.3M	4.79M	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.98M	-3.77M	-4.98M	-6.57M	-5.71M	-1.34M	-5.72M	-8.48M	-7.86M	-7.86M
Operating CF Margin %	-	13.45%	-	23.48%	-	-	-	-	-	-
Operating CF Growth %	-	-0.9%	-0.32%	-0.32%	0.13%	0.77%	-3.27%	-0.48%	0.07%	0%
Net Income	-2.62M	-4M	-7.91M	-5.59M	-4.72M	-2.1M	-21.46M	-9.38M	-8.69M	-9.01M
Depreciation & Amortization	18.27K	89.13K	104.22K	125.72K	227.06K	104.04K	104.04K	104.04K	103.71K	100K
Stock-Based Compensation	0	0	0	0	0	0	0	764.01K	1.09M	1.26M
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	134.59K	215.9K	2.54M	-1.1M	-858.83K	378.33K	15.01M	127.06K	-471.31K	-209.05K
Working Capital Changes	258.64K	54.89K	245.71K	233.92K	-358.69K	274.36K	632.33K	-94.35K	95.2K	-2.14K
Change in Receivables	-84.41K	-274.19K	131.68K	11.96K	108.05K	60.19K	0	0	0	0
Change in Inventory	0	0	0	0	0	-60.19K	0	0	0	0
Change in Payables	343.05K	329.08K	114.03K	0	0	227.31K	1.35M	-217.81K	53.78K	275.95K
Cash from Investing+	817.09K	-4.71M	2.83M	3.81M	-30.31K	-125K	-625K	-10.15M	2.19M	-1.89M
Capital Expenditures	-85.44K	-330.64K	-74.53K	-182.46K	-34.52K	-125K	-625K	-250K	0	0
CapEx % of Revenue	-	-1.18%	-	-0.65%	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	2.99M	3.83M	0	0	0	-14.88B	5.64K	-9.68B
Cash from Financing+	1.65M	9.13M	4.43M	3.55M	6.14M	1.79M	13.5M	14.01M	5.22M	10.97M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	-65.27M	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	0	1.02M	10.03M	64.77M	-17.51K	-54.9K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-2.07M	-4.1M	-5.05M	-6.76M	-5.74M	-1.46M	-6.35M	-8.73M	-7.86M	-7.86M
FCF Margin %	-	14.63%	-	24.13%	-	-	-	-	-	-
FCF Growth %	-	-0.98%	-0.23%	-0.34%	0.15%	0.75%	-3.34%	-0.38%	0.1%	0%
FCF per Share	-1667.69	-2699.38	-2708.01	-3132.31	-1620.30	-73.09	-3973.13	-21.62	-305.52	-58.65
FCF Conversion (FCF/Net Income)	0.76x	-0.25x	-0.49x	-0.43x	3.66x	0.64x	0.27x	0.90x	0.91x	0.88x
Interest Paid	0	0	0	0	0	0	393.61K	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-97%	303.29%	158.54%	334.57%	-38.91%	-	-3266.6%	-232.68%	-132.92%	-120.55%
Return on Invested Capital (ROIC)	-	307.22%	210.18%	5290.25%	-	-	-	-	-180.15%	-161.61%
Gross Margin	-	131.83%	-	144.9%	-	-	-	-	-	-
Net Margin	-	-5470.36%	-	-5470.36%	-	-	-	-	-	-
Debt / Equity	-	0.00x	-	-	0.07x	-	-	-	-	-
Interest Coverage	-	-	-	-	-3.78x	-1.41x	-5.56x	-12.96x	-	-
FCF Conversion	0.76x	-0.25x	-0.49x	-0.43x	3.66x	0.64x	0.27x	0.90x	0.91x	0.88x
Revenue Growth	-	-	100%	-	100%	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Quoin Pharmaceuticals, Ltd. (QNRX) grew revenue by 0.0% over the past year. Growth has been modest.

Quoin Pharmaceuticals, Ltd. (QNRX) reported a net loss of $13.8M for fiscal year 2024.

Dividend & Returns

Quoin Pharmaceuticals, Ltd. (QNRX) has a return on equity (ROE) of -120.6%. Negative ROE indicates the company is unprofitable.

Quoin Pharmaceuticals, Ltd. (QNRX) had negative free cash flow of $10.7M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Quoin Pharmaceuticals, Ltd. (QNRX) 10-Year Financial Performance & Capital Metrics

QNRX • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

Revenue $0
EBITDA -$9M -1.7%
Net Income -$9M -3.2%
EPS (Diluted) -66.85 +80.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -120.55% +9.3%
ROIC -161.61% +10.3%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 84 (top 16%)
✓Trading at only 0.2x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-58.23%

EPS CAGR

10Y-

5Y-

3Y-

TTM-59.02%

ROCE

10Y Avg12.8%

5Y Avg-108.87%

3Y Avg-102.89%

Latest-94.73%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	-280K	0	-280K	0	0	0	0	0	0
Revenue Growth %	-	-	1%	-	1%	-	-	-	-	-
Cost of Goods Sold+	18.27K	89.13K	104.22K	125.72K	227.06K	0	0	0	0	0
COGS % of Revenue	-	-0.32%	-	-0.45%	-	-	-	-	-	-
Gross Profit+	-18.27K	-369.13K	-104.22K	-405.72K	-227.06K	0	0	0	0	0
Gross Margin %	-	1.32%	-	1.45%	-	-	-	-	-	-
Gross Profit Growth %	-	-19.2%	0.72%	-2.89%	0.44%	1%	-	-	-	-
Operating Expenses+	2.58M	16.22M	10.1M	16.22M	1.56M	1.67M	6.06M	9.26M	9.38M	9.53M
OpEx % of Revenue	-	-57.94%	-	-57.94%	-	-	-	-	-	-
Selling, General & Admin	1.06M	7.97M	4.2M	7.97M	1.51M	1.43M	4.5M	6.58M	6.07M	5.93M
SG&A % of Revenue	-	-28.46%	-	-28.46%	-	-	-	-	-	-
Research & Development	1.52M	8.26M	5.89M	8.26M	45.65K	244.16K	1.56M	2.67M	3.31M	3.6M
R&D % of Revenue	-	-29.49%	-	-29.49%	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-2.6M	15.32M	10.17M	15.32M	-1.56M	-1.67M	-6.06M	-9.26M	-9.38M	-9.53M
Operating Margin %	-	-54.7%	-	-54.7%	-	-	-	-	-	-
Operating Income Growth %	-	6.89%	-0.34%	0.51%	-1.1%	-0.07%	-2.63%	-0.53%	-0.01%	-0.02%
EBITDA+	-2.58M	15.41M	10.28M	15.44M	-1.33M	-1.57M	-5.96M	-9.15M	-9.27M	-9.43M
EBITDA Margin %	-	-55.02%	-	-55.15%	-	-	-	-	-	-
EBITDA Growth %	-	6.97%	-0.33%	0.5%	-1.09%	-0.17%	-2.81%	-0.54%	-0.01%	-0.02%
D&A (Non-Cash Add-back)	18.27K	89.13K	104.22K	125.72K	227.06K	104.04K	104.04K	104.04K	103.71K	100K
EBIT	-2.62M	-3.99M	-7.91M	-5.59M	-4.31M	-1.67M	-20.37M	-8.67M	-9.38M	-9.53M
Net Interest Income+	0	0	0	0	-412.29K	-1.19M	-1.09M	-618.34K	694.61K	558.49K
Interest Income	1.03K	0	0	0	0	0	0	95.75K	694.61K	558.49K
Interest Expense	0	0	0	0	412.29K	1.19M	1.09M	714.08K	0	0
Other Income/Expense	-19.3K	237.07K	-1.06M	2.54M	0	-425.35K	-15.4M	-123.79K	691.93K	565.99K
Pretax Income+	-2.62M	15.32M	10.17M	15.32M	-1.56M	-2.1M	-21.46M	-9.38M	-8.69M	-8.96M
Pretax Margin %	-	-54.7%	-	-54.7%	-	-	-	-	-	-
Income Tax+	0	147.94K	-1.17M	-161.14K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-2.62M	15.32M	10.17M	15.32M	-1.56M	-2.1M	-21.46M	-9.38M	-8.69M	-8.96M
Net Margin %	-	-54.7%	-	-54.7%	-	-	-	-	-	-
Net Income Growth %	-	6.85%	-0.34%	0.51%	-1.1%	-0.34%	-9.24%	0.56%	0.07%	-0.03%
Net Income (Continuing)	-2.62M	-4M	-7.91M	-5.59M	-1.56M	-2.1M	-21.46M	-9.38M	-8.69M	-8.96M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2108.97	10084.00	5450.81	7100.73	-440.29	-88.10	-28543.20	-22.97	-337.47	-66.85
EPS Growth %	-	5.78%	-0.46%	0.3%	-1.06%	0.8%	-322.99%	1%	-13.69%	0.8%
EPS (Basic)	-2108.97	10084.00	5450.81	7100.73	-440.29	-88.10	-28543.20	-22.97	-337.47	-66.85
Diluted Shares Outstanding	1.24K	1.52K	1.87K	2.16K	3.54K	20.02K	1.6K	403.88K	25.74K	133.96K
Basic Shares Outstanding	1.24K	1.52K	1.87K	2.16K	3.54K	20.02K	1.6K	403.88K	25.74K	133.96K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	3.12M	8.42M	8.22M	4.98M	5.38M	465.17K	8.2M	13.37M	11.29M	14.93M
Cash & Short-Term Investments	3.02M	8.04M	7.99M	4.77M	5.24M	323.83K	7.48M	12.85M	10.69M	14.06M
Cash Only	1.01M	1.63M	3.96M	4.77M	5.24M	323.83K	7.48M	2.86M	2.4M	3.62M
Short-Term Investments	2.01M	6.41M	4.03M	0	0	0	0	9.99M	8.29M	10.43M
Accounts Receivable	48.06K	172.01K	70.57K	57.8K	77.3K	0	0	0	0	0
Days Sales Outstanding	-	-224.22	-	-75.35	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	141.34K	0	0	32.58K	0
Total Non-Current Assets+	310.2K	393.12K	524.83K	538.7K	794.73K	912.65K	1.16M	1.09M	883.33K	783.33K
Property, Plant & Equipment	305.06K	356.75K	387.14K	413.19K	672.55K	1.94M	0	0	0	0
Fixed Asset Turnover	-	-0.78x	-	-0.68x	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	1.02M	912.65K	808.6K	704.56K	583.33K	483.33K
Long-Term Investments	5.14K	36.38K	137.69K	125.51K	122.18K	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	-1.02K	-1.94M	350K	383.39K	300K	300K
Total Assets+	3.43M	8.81M	8.75M	5.52M	6.17M	1.38M	9.36M	14.46M	12.17M	15.71M
Asset Turnover	-	-0.03x	-	-0.05x	-	-	-	-	-	-
Asset Growth %	-	1.57%	-0.01%	-0.37%	0.12%	-0.78%	5.79%	0.55%	-0.16%	0.29%
Total Current Liabilities+	735.02K	905.51K	1.18M	1.31M	1.05M	7.99M	4.58M	3.53M	3.58M	4.18M
Accounts Payable	119.76K	348.95K	490.55K	237.37K	45.74K	0	923.24K	605.6K	526.52K	905.7K
Days Payables Outstanding	2.39K	1.43K	1.72K	689.16	73.54	-	-	-	-	-
Short-Term Debt	0	15.07K	0	0	114.65K	1.21M	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	444.87K	541.49K	127.32K	1.07M	637.81K	0	373.6K	0	0	0
Current Ratio	4.25x	9.30x	6.97x	3.80x	5.11x	0.06x	1.79x	3.79x	3.15x	3.57x
Quick Ratio	4.25x	9.30x	6.97x	3.80x	5.11x	0.06x	1.79x	3.79x	3.15x	3.57x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	503.55K	2.14M	485.98K	824.84K	0	4.12M	3.52M	2.92M	2.32M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	196K	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	503.55K	2.14M	485.98K	628.84K	0	4.12M	3.52M	2.92M	2.32M
Total Liabilities	735.02K	1.41M	3.32M	1.8M	1.88M	7.99M	8.7M	7.05M	6.51M	6.5M
Total Debt+	0	15.07K	0	0	310.65K	1.21M	0	0	0	0
Net Debt	-1.01M	-1.62M	-3.96M	-4.77M	-4.93M	889.48K	-7.48M	-2.86M	-2.4M	-3.62M
Debt / Equity	-	0.00x	-	-	0.07x	-	-	-	-	-
Debt / EBITDA	-	0.00x	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-0.10x	-0.38x	-0.31x	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-3.78x	-1.41x	-5.56x	-12.96x	-	-
Total Equity+	2.7M	7.4M	5.43M	3.73M	4.3M	-6.61M	657.03K	7.41M	5.66M	9.2M
Equity Growth %	-	1.74%	-0.27%	-0.31%	0.15%	-2.54%	1.1%	10.27%	-0.24%	0.63%
Book Value per Share	2174.66	4876.01	2910.14	1727.38	1212.08	-329.97	411.42	18.34	220.04	68.71
Total Shareholders' Equity	2.7M	7.4M	5.43M	3.73M	4.3M	-6.61M	657.03K	7.41M	5.66M	9.2M
Common Stock	0	0	0	0	100	0	0	0	0	0
Retained Earnings	-5.24M	-9.28M	-18.42M	-22.49M	-29.2M	-6.61M	-28.07M	-37.52M	-46.2M	-55.17M
Treasury Stock	-2.42M	-2.45M	-2.71M	-2.52M	-2.73M	0	-2.93M	-2.93M	0	0
Accumulated OCI	972.49K	1.62M	2.7M	3.3M	4.79M	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.98M	-3.77M	-4.98M	-6.57M	-5.71M	-1.34M	-5.72M	-8.48M	-7.86M	-7.86M
Operating CF Margin %	-	13.45%	-	23.48%	-	-	-	-	-	-
Operating CF Growth %	-	-0.9%	-0.32%	-0.32%	0.13%	0.77%	-3.27%	-0.48%	0.07%	0%
Net Income	-2.62M	-4M	-7.91M	-5.59M	-4.72M	-2.1M	-21.46M	-9.38M	-8.69M	-9.01M
Depreciation & Amortization	18.27K	89.13K	104.22K	125.72K	227.06K	104.04K	104.04K	104.04K	103.71K	100K
Stock-Based Compensation	0	0	0	0	0	0	0	764.01K	1.09M	1.26M
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	134.59K	215.9K	2.54M	-1.1M	-858.83K	378.33K	15.01M	127.06K	-471.31K	-209.05K
Working Capital Changes	258.64K	54.89K	245.71K	233.92K	-358.69K	274.36K	632.33K	-94.35K	95.2K	-2.14K
Change in Receivables	-84.41K	-274.19K	131.68K	11.96K	108.05K	60.19K	0	0	0	0
Change in Inventory	0	0	0	0	0	-60.19K	0	0	0	0
Change in Payables	343.05K	329.08K	114.03K	0	0	227.31K	1.35M	-217.81K	53.78K	275.95K
Cash from Investing+	817.09K	-4.71M	2.83M	3.81M	-30.31K	-125K	-625K	-10.15M	2.19M	-1.89M
Capital Expenditures	-85.44K	-330.64K	-74.53K	-182.46K	-34.52K	-125K	-625K	-250K	0	0
CapEx % of Revenue	-	-1.18%	-	-0.65%	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	2.99M	3.83M	0	0	0	-14.88B	5.64K	-9.68B
Cash from Financing+	1.65M	9.13M	4.43M	3.55M	6.14M	1.79M	13.5M	14.01M	5.22M	10.97M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	-65.27M	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	0	1.02M	10.03M	64.77M	-17.51K	-54.9K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-2.07M	-4.1M	-5.05M	-6.76M	-5.74M	-1.46M	-6.35M	-8.73M	-7.86M	-7.86M
FCF Margin %	-	14.63%	-	24.13%	-	-	-	-	-	-
FCF Growth %	-	-0.98%	-0.23%	-0.34%	0.15%	0.75%	-3.34%	-0.38%	0.1%	0%
FCF per Share	-1667.69	-2699.38	-2708.01	-3132.31	-1620.30	-73.09	-3973.13	-21.62	-305.52	-58.65
FCF Conversion (FCF/Net Income)	0.76x	-0.25x	-0.49x	-0.43x	3.66x	0.64x	0.27x	0.90x	0.91x	0.88x
Interest Paid	0	0	0	0	0	0	393.61K	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-97%	303.29%	158.54%	334.57%	-38.91%	-	-3266.6%	-232.68%	-132.92%	-120.55%
Return on Invested Capital (ROIC)	-	307.22%	210.18%	5290.25%	-	-	-	-	-180.15%	-161.61%
Gross Margin	-	131.83%	-	144.9%	-	-	-	-	-	-
Net Margin	-	-5470.36%	-	-5470.36%	-	-	-	-	-	-
Debt / Equity	-	0.00x	-	-	0.07x	-	-	-	-	-
Interest Coverage	-	-	-	-	-3.78x	-1.41x	-5.56x	-12.96x	-	-
FCF Conversion	0.76x	-0.25x	-0.49x	-0.43x	3.66x	0.64x	0.27x	0.90x	0.91x	0.88x
Revenue Growth	-	-	100%	-	100%	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Quoin Pharmaceuticals, Ltd. (QNRX) grew revenue by 0.0% over the past year. Growth has been modest.

Quoin Pharmaceuticals, Ltd. (QNRX) reported a net loss of $13.8M for fiscal year 2024.

Dividend & Returns

Quoin Pharmaceuticals, Ltd. (QNRX) has a return on equity (ROE) of -120.6%. Negative ROE indicates the company is unprofitable.

Quoin Pharmaceuticals, Ltd. (QNRX) had negative free cash flow of $10.7M in fiscal year 2024, likely due to heavy capital investments.